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Background: Cryptococcus neoformans, a basidiomycetous fungus of universal occurrence, is a significant
opportunistic human pathogen causing meningitis. Owing to an increase in the number of immunosuppressed
individuals along with emergence of drug-resistant strains, C. neoformans is gaining importance as a pathogen.
Although, whole genome sequencing of three varieties of C. neoformans has been completed recently, no global
proteomic studies have yet been reported.
Results: We performed a comprehensive proteomic analysis of C. neoformans var. grubii (Serotype A), which is the
most virulent variety, in order to provide protein-level evidence for computationally predicted gene models and to
refine the existing annotations. We confirmed the protein-coding potential of 3,674 genes from a total of 6,980
predicted protein-coding genes. We also identified 4 novel genes and corrected 104 predicted gene models. In
addition, our studies led to the correction of translational start site, splice junctions and reading frame used for
translation in a number of proteins. Finally, we validated a subset of our novel findings by RT-PCR and sequencing.
Conclusions: Proteogenomic investigation described here facilitated the validation and refinement of
computationally derived gene models in the intron-rich genome of C. neoformans, an important fungal pathogen
in humans.
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Genome annotationBackground
Cryptococcus neoformans is an opportunistic human pa-
thogen, which causes cryptococcal meningitis, mostly
among immune-impaired individuals [1,2]. Cryptococcus
neoformans species complex comprises of two subspecies
(C. neoformans and C. gattii), two varieties (C. neoformans
var. grubii and C. neoformans var. neoformans) and five
serotypes – Serotype A (C. neoformans var. grubii), Sero-
type D and Serotype AD (C. neoformans var. neoformans)* Correspondence: harsha@ibioinformatics.org; keshav@ibioinformatics.org
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distribution, and reproduction in any mediumand Serotype B and C (C. gattii) [3,4]. Whole genome se-
quencing of C. neoformans var. neoformans [5], C. neofor-
mans var. grubii [6] and C. gattii [7] has been carried out
recently. C. neoformans var. grubii (Serotype A) is the pre-
dominant disease-causing variety worldwide and accounts
for about 95% of cryptococcal infections [8,9]. The nuclear
genome of C. neoformans var. grubii is approximately
19 Mb in size, which is organized into 14 chromosomes
predicted to encode 6,967 protein-coding genes [6]. More
than 98% of these protein-coding genes contain short
introns [10]. These introns add to the complexity of
genome through alternative splicing, exon skipping or
truncation/extension at their 5′ or 3′ ends. Therefore, ex-
perimental approaches are required in order to refine thesed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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been used to verify some of the gene models in C. neofor-
mans var. grubii [11,12]. In this study, we used high accur-
acy mass spectrometry-derived data as a complementary
approach to validate and improve the annotation of C. neo-
formans var. grubii.
Proteogenomics complements other genome annota-
tion methods [13-15]. In addition to validating predicted
genes, proteogenomics can be used to identify novel
proteins, novel exons, novel translational start sites and
protein isoforms based on the identification of novel
splice junctions. Proteogenomic analysis has been previ-
ously employed to refine annotation of protein-coding
genes in genomes of several organisms including human
[16,17], Drosophila [18], C. elegans [19,20] and microor-
ganisms (e.g. Saccharomyces cerevisiae [21,22], Aspergillus
niger [23], Mycobacterium tuberculosis [24,25], Candida
glabrata [26] and Escherichia coli [27]). In this study, we
carried out an in-depth proteomic analysis of C. neofor-
mans var. grubii to identify novel protein-coding regions
in its genome in addition to the validation of predicted
genes from this genome. For this, we subjected culture
lysates of C. neoformans var. grubii to various fraction-
ation methods followed by proteomic analysis on an LTQ-
Orbitrap Velos mass spectrometer. We searched MS/MS
data against protein database of C. neoformans var. grubii,
which provided peptide evidence for 52% of the total
annotated protein-coding genes. By searching MS/MS
data against a six-frame translated genome database,
we also identified 286 novel peptides with good spec-
tral assignments that were unique to C. neoformans
var. grubii genome. By corroborating these peptide se-
quences with ESTs and comparative genomics data,
we identified 4 novel genes and revised the annota-
tion of 104 gene structures in 111 instances. Finally,
we also confirmed the annotated translational start
sites of 524 proteins and identified 65 novel splice
junctions.
Results and discussion
To carry out a comprehensive analysis, we utilized a
multipronged approach for protein/peptide fractionation
including SDS-PAGE at the protein level and bRPLC
and SCX at the peptide level. Seventy fractions (22 frac-
tions from SDS-PAGE, 24 from bRPLC and 24 from
SCX) were subjected to LC-MS/MS analysis. Overall,
485,714 MS/MS spectra obtained were searched against
three databases, i) protein database containing sequences
of 6,980 known/predicted proteins of C. neoformans var.
grubii as reported in the genome database hosted by the
Broad Institute (http://www.broadinstitute.org/annotation/
genome/cryptococcus_neoformans/MultiHome.html);
ii) six-frame translated genome database; and iii) N-
acetylated peptide database.Proteomic evidence for predicted protein-coding genes in
C. neoformans var. grubii
A search of the MS/MS data against the C. neoformans
var. grubii protein database resulted in the identification
of 184,030 peptide-spectrum matches (PSMs) that were
filtered for first rank assignments and passed a 1% FDR
cut-off. These PSMs resulted in the identification of
30,570 unique peptides, which corresponded to 3,674
proteins (52% of C. neoformans var. grubii proteome).
Peptides and proteins identified in this study are provi-
ded as Additional file 1: Table S1 and Additional file 2:
Table S2 respectively. Of these, multiple peptides sup-
ported the identification of 2,868 proteins, whereas 249
proteins are supported by a single peptide with more
than one PSM for each peptide while 557 proteins are
associated with a single peptide and a single PSM. We
used multiple strategies for the isolation and fraction-
ation of C. neoformans var. grubii proteome to increase
the proteome coverage, which is evident with proteins
exclusively identified in SDS-PAGE (359), SCX (378) and
bRPLC (248) fractions (Figure 1A). We also obtained
similar results in our previous proteogenomic analyses of
M. tuberculosis and C. glabrata [24,26].
Genome annotation of C. neoformans var. grubii
predicted 6,967 protein-coding genes from its nuclear
genome and 13 protein-coding genes from its mitochon-
drial genome. Of the 6,980 annotated protein-coding
genes, 2,200 genes were annotated based only on compu-
tational predictions and lacked any experimental evidence
[6]. Our proteomic study has provided experimental valid-
ation, for the first time, for 746 protein-coding genes, cov-
ering 33% of genes which did not have any experimental
evidence at the RNA or protein level. On the other hand,
of the remaining 4,780 genes that had cDNA evidence,
we identified 2,928 (61%) gene products. We observed
a skewed detection ratio between computationally
predicted genes (33%) and experimentally supported
genes (61%), which was evident from global and unbiased
approach used in this study, suggesting the fact that some
of the computational predictions might not be true
protein-coding genes. Rodrigues et al., have investigated
the proteome of extracellular vesicles of C. neoformans
and identified 76 proteins [28]. Using 2-DE and MALDI-
TOF, Missall et al., identified 32 proteins that were altered
in response to nitric oxide stress in C. neoformans [29].
We have identified peptides belonging to 3,674 annotated
protein-coding genes, which includes 10 proteins coded
by mitochondrial genome. This constitutes ~50% coverage
of the predicted protein-coding genes from the analysis of
a single growth condition used in this study. The reason
that we did not detect all of the proteins in this study is
likely due to the fact that not all genes are expressed
under a single growth condition (Loftus et al. subjected C.
neoformans JEC21 (Serotype D) to 14 different growth
A B
CNAG_06125  - translation elongation factor 1 
alpha
CNAG_03007 - conserved hypothetical protein
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CNAG_06101 - eukaryotic ADP/ATP carrier
CNAG_01984 - transaldolase 
CNAG_04659 - pyruvate decarboxylase
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Figure 1 Proteomics of C. neoformans var. grubii. A) Venn diagram representing the number of proteins identified using different fractionation
methods B) Scatter plot showing the normalized spectral abundance factor analysis of top 50 proteins identified in our study.
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protein-coding genes [5]) and that we did not identify
proteins present at really low abundance. Another con-
tributing factor could be that some of the computational
predictions for protein-coding genes are false positives
and thus cannot be experimentally verified.
Relative abundance of the identified cryptococcal pro-
teins was determined by normalized spectral abundance
factor. Proteins involved in translation (e.g. translation
elongation factor 1 alpha) and metabolism (e.g. man-
nitol −1- phosphate dehydrogenase, transaldolase, pyru-
vate decarboxylase, D-lactaldehyde dehydrogenase) were
among the most abundant proteins identified (Figure 1B
and Additional file 2: Table S2).
Genome search-specific peptides (GSSPs)
GSSPs are those peptides, which are identified from the
search of MS/MS data against six-frame translated gen-
ome database but are not represented in the known pro-
tein databases. In our study, search of MS/MS spectra
against six-frame translated genome database resulted in
identification of 134,453 PSMs corresponding to 22,377
peptides. Among these, 768 novel peptides did not
belong to any of the known proteins in C. neoformans
var. grubii. Of the 768 novel peptides unique to genome
database search, 286 peptides passed manual validation
for good spectral assignments. Those peptides that passed
manual validation were the only ones considered for fur-
ther analysis. We also discarded any peptides that had
multiple hits in the genome or were post-translationally
modified. Of the 286 peptides analyzed for gene models
based on orthology-based evidence and gene prediction
models, 144 peptides contributed to identification of 4novel genes and 111 revised gene models (Figure 2 and
Table 1).
Since use of hypothetical databases such as 6-frame
translated genome database for peptide identification
might, in theory, increase the chance of false identifica-
tions, we plotted the score distribution of peptides from
protein database search and the genome search-specific
peptides (from six frame translation search) and found
that the score was indeed lower for the GSSPs (Additional
file 3: Figure S1) [30]. This is in agreement with our find-
ing that only 286 out of 768 GSSPs passed our manual
verification. Overall, we believe that our approach is a
conservative approach and that we might have a number
of false negatives because of technical reasons (FDR
threshold, no modifications allowed, no ionizable peptides
in the detection range, only unique hits considered, only
one missed cleavage allowed) as well as biological ones
(exon-exon spanning peptides will be missed). We carried
out RT-PCR for 50 gene models and were able to validate
47 novel genes and revised gene models (see details
below). We believe that we were able to achieve an overall
success rate of 94% for these validation studies because of
the conservative approach adopted in our study.
Identification of novel protein-coding genes
Novel protein-coding genes in the genome were identi-
fied using GSSPs that mapped to intergenic regions. We
propose 4 novel gene models with additional evidence in
the form of orthology and ESTs (Table 2). Subsequently,
these novel genes were also validated by cDNA sequen-
cing (Figure 3). Novel protein 1 (CNAG_IOB_PROT1)
of length 358 amino acids was identified based on two
GSSPs that mapped to the intergenic region between
 MS/MS spectra 
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Figure 2 Schematic workflow of proteogenomic analysis. Mass spectrometry derived data was searched against protein database and six-frame
translated genome database of C. neoformans var. grubii. Peptides mapping to the protein database confirmed annotated proteins and annotated
splice junctions. C represents the number of peptides identified mapping to exons excluding A and B. Peptides unique to six-frame translated genome
database were categorized based on their mapping to intergenic regions and regions within the annotated genes. These peptides were used to refine
the annotation of genome.
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chromosome 1. This novel protein was found to be hom-
ologous to monoubiquitination related protein of Crypto-
coccus neoformans var. neoformans JEC21 (XP_566713.1).
The second novel protein was identified based on two
GSSPs DLEIGAPVSIGDTPSPEDK and SLSPEVQASLPA-
DIR, which mapped to the intergenic region between
CNAG_03798 and CNAG_03805 genes on chromosomeTable 1 Summary of novel findings in proteogenomic
analysis of C. neoformans var. grubii
Categories Novel identifications/
refinement of gene models
Novel genes 4
Novel exons 17
Refinement of gene boundaries 19
Refinement of exon boundaries 53
Protein coding evidence in UTRs 13
Correction of translational frame 8
Novel protein start site 12. Analysis of this intergenic region using alternate gene
prediction programs revealed a novel protein-coding
region (CNAG_IOB_PROT2) homologous to integrase
rve protein of C. neoformans var. neoformans B-3501A
(XP_777044.1). The third novel protein-coding gene was
identified in an intergenic region on chromosome 5 based
on a single GSSP between CNAG_07399 and CNAG_
06854 genes. BLASTX analysis of this intergenic region
revealed a novel open reading frame (CNAG_IOB_
PROT3) of 355 amino acids. This novel protein is similar
to a hypothetical protein in C. neoformans var. neoformans
JEC21 (XP_570553.1). Three GSSPs, WGILEGEFGK,
LTFQFITSSEK and LVNEGDWEGGLSEVEDIVR, were
clustered in the intergenic region between CNAG_01461
and CNAG_01463 genes on chromosome 11. Analysis of
this intergenic region revealed a novel protein-coding
region (CNAG_IOB_PROT4) encoding a 1,292 amino
acid residues long protein. This novel protein was found
to be homologous to retrograde transport, endosome to
Golgi-related protein in C. neoformans var. neoformans
(Serotype D and Serotype AD) and C. gattii (Serotype B
Table 2 List of novel proteins identified in C. neoformans var. grubii
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Figure 3 RT-PCR based validation of novel and revised gene models. RT-PCR validation was carried out for 47 novel and revised gene models.
Transcript identifier for each gene model is indicated above each lane. These RT-PCR products were sequenced and submitted to GenBank.
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http://www.clinicalproteomicsjournal.com/content/11/1/5and C). Illustration of novel genes CNAG_IOB_PROT1
and CNAG_IOB_PROT4 is provided in Figure 4. MS/MS
spectra of novel peptides belonging to these novel genes
are shown in Additional file 4: Figure S2.
Confirmation and correction of splice junctions
C. neoformans genome has a relatively complex gene struc-
ture with an average of 5 short introns per gene of average
size of ~67 bases. Determination of exon-boundaries insuch short intron-rich genome is known to be challenging
[5]. Therefore, accuracy of splice sites proposed by gene
prediction programs can be verified using proteomic evi-
dence in the form of splice-junction peptides. Peptides
encompassing these splice junctions would be useful in
verifying the splice sites or in annotating the existence of
novel ones [10]. Our proteomic approach enabled us to
identify 5,136 peptides mapping to exon–exon junctions
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Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Identification of novel protein-coding genes based on peptides mapping to intergenic regions. A) GSSP mapped to intergenic
region in Chromosome 1 between CNAG_00389 and CNAG_00390. Gene prediction programs predicted 358 amino acids long proteins from this
region, which is homologous to monoubiquitination protein of C. neoformans var. neoformans. B) Three peptides mapped to intergenic region
between CNAG_01461 and CNAG_01463. Gene prediction programs predicted protein-coding gene in this region. The predicted protein has
homology to retrograde transport, endosome to Golgi related protein, XP_776934.1 (C. neoformans var. neoformans B-3501A), XP_569839.1
(C. neoformans var. neoformans JEC21), XP_003192571.1 (C. gattii WM276). C) The MS/MS spectra of intergenic peptides STPLTVSEDQEDELLSIVPIK
and LTFQFITSSEK are shown.
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http://www.clinicalproteomicsjournal.com/content/11/1/5splice sites in C. neoformans var. grubii genome and simul-
taneously validated short introns predicted from computa-
tional prediction pipelines. We have provided a list of these
splice junction peptides in Additional file 5: Table S3.
In addition to validating predicted exon-exon boundar-
ies in the intron rich genome of C. neoformans var. grubii,
we also identified novel exons and refined the structures
of several annotated exons. GSSPs which overlapped
exons and associated intronic regions aided in the iden-
tification of novel exons and also in revising the splice
junctions for the corresponding genes. Seventeen novel
exons were identified using 20 unique peptides mapping
to intronic regions (Table 3). Of these, 7 novel exons were
validated by RT-PCR and confirmed by cDNA sequencing
(Figure 3; Table 3). Introns following these 17 novel exons
were found to have the canonical splicing signals [10].
We found 53 examples of exon extensions, thereby revis-
ing the corresponding predicted gene models (Additional
file 6: Table S4). These exon extensions were also supported
by the presence of similar sequences in orthologous genes.
In addition, we validated a subset of these exon extensions
by cDNA sequencing (Figure 3). Of the 53 cases of exon
extension, splice donor site was revised in 37 cases while
the splice acceptor site was revised in remaining 16 cases.
These altered splice acceptor and donor sites had the ca-
nonical splice acceptor sites – 5′GU and 5′ GC and splice
donor site – 3′AG [10]. Additional file 7: Figure S3 shows
an example of exon extension through identification of
peptides mapping to intron and exon–intron junction of
CNAG_02460. The current annotation of CNAG_02460
comprises 4 exons. We identified 19 peptides mapping to
first and second exon of CNAG_02460. From GSSP ana-
lysis, we found one peptide mapping to junction of second
exon and second intron and two peptides mapping to the
second intron. These peptides supported a model in which
the two exons could be merged. We validated this exon ex-
tension by RT-PCR and cDNA sequencing (Figure 3).
Refinement of coding DNA sequence coordinates
Coding DNA Sequence (CDS), the portion of genomic
DNA sequence composed of exons that is translated
into protein, is often delineated by gene prediction algo-
rithms. Incorrect prediction of translational start sites
and stop codons are frequently encountered in ab initio
predicted gene models. Peptides mapping to upstream anddownstream of genes suggest changes to CDS boundaries
of genes. These peptides alter the annotated translational
start sites or stop codons resulting in the extension of
annotated genes either towards N-terminus or C-terminus
of proteins, respectively. In this study, we extended N-
termini of 14 proteins using 18 GSSPs as evidence; and C-
termini of 5 proteins using 5 GSSPs mapping either to
intergenic region or junction of intergenic region and CDS
(Additional file 8: Table S5). N-terminal extension of
CNAG_05600 protein with a peptide mapping upstream of
the gene is depicted in Additional file 9: Figure S4. The
peptide extended the CNAG_05600 protein, which belongs
to indigoidine synthase A family, from 707 amino acids to
773 amino acids. The newly extended part of this gene is
found to be conserved in other serotypes of Cryptococcus.
Analysis of another intergenic peptide, which mapped
downstream of gene CNAG_00409, using alternate gene
prediction programs extended the C-terminus of protein.
The revised protein has an orthologous protein in C. neo-
formans var. neoformans B-3501A (XP_777909.1) and C.
neoformans var. neoformans JEC21 (XP_566744.1). We
have validated these gene extensions by RT-PCR and sub-
mitted sequences of these cDNAs to GenBank (Figure 3).
In another type of refinement of CDS co-ordinates
using GSSPs mapping to UTRs, we found 8 instances
of N-terminal in-frame extensions using peptides that
mapped to 5′ UTR of genes and 5 cases of C-terminal
extensions with the aid of peptides mapping to 3′ UTR
of genes (Additional file 10: Table S6). For instance,
CNAG_01159 gene was annotated to code for 466 amino
acids long pre-mRNA splicing factor SLU7 protein. We
identified a peptide in 5′ UTR of the gene and were able
to extend the protein at N-terminus resulting in a 586
amino acids long protein, which is conserved in C. neo-
formans var. neoformans, Coprinopsis cinerea okayama
and Ustilago maydis. We also extended C-terminus of
CNAG_00768 protein to 368 amino acids, which was an-
notated to be 164 amino acids long, by finding 4 peptides
mapping to 3′ UTR of its gene (Additional file 11: Figure
S5). The extended protein was found to be conserved in
C. neoformans var. neoformans and C. gattii.
Alternate frame of translation
Identification of the correct reading frame is essential to
confirm the translational read out of hypothetical proteins.
Table 3 List of novel exons identified using peptide evidence in C. neoformans var. grubii
Gene ID Genome search specific peptide Novel exon co – ordinates GenBank Accession
(Transcript identifier)
Orthologous evidence for novel exons identified by GSSPs
1 CNAG_02122 AcALLEGLESGLSR Chr 6: 1136454 – 1136507; Negative GenBank: JZ152661.1
(CNAG_02122_NE1)
XP_571070.1 (Cryptococcus neoformans var. neoformans JEC21); XP_003194441.1
(Cryptococcus gattii WM276); EIW67330.1 (Tremella mesenterica DSM 1558)
2 CNAG_02773 TAITIKPALAAQAGK Chr 3: 801827 – 801913; Negative GenBank: JZ152662.1
(CNAG_02773_NE2)
XP_003192989.1 (Cryptococcus gattii WM276); XP_570007.1 (Cryptococcus
neoformans var. neoformans JEC21)
3 CNAG_03648 VIFVDADQIVR Chr 2: 438306 – 438539; Positive GenBank: JZ152663.1
(CNAG_03648_NE3)
XP_777193.1 (Cryptococcus neoformans var. neoformans B-3501A); XP_388116.1
(Gibberella zeae PH-1); XP_001832620.2 (Coprinopsis cinerea okayama7#130);
4 CNAG_03920 YYDLGMESR Chr 2: 1190442 – 1190507; Positive GenBank: JZ152664.1
(CNAG_03920_NE4)
XP_569234.1 (Cryptococcus neoformans var. neoformans JEC21); XP_003191314.1
(Cryptococcus gattii WM276)
5 CNAG_06526 TYPLALDLWDSGSSVIIR; IASFPLNFISR Chr 7: 12832–13094; Positive GenBank: JZ152665.1
(CNAG_06526_NE5)
XP_567229.1 (Cryptococcus neoformans var. neoformans JEC21)
6 CNAG_06533 SNGYYSPITYFLAK; LLFDIIPLR Chr 7: 36868 – 37134; Positive GenBank: JZ152666.1
(CNAG_06533_NE6)
XP_571629.1 (Cryptococcus neoformans var. neoformans JEC21); XP_003194552.1
(Cryptococcus gattii WM276); XP_757847.1 (Ustilago maydis 521); XP_750621.1
(Aspergillus fumigatus Af293)
7 CNAG_02396 FNGPVDFER Chr 6: 435584 – 435658; Positive GenBank: JZ152667.1
(CNAG_02396_NE7)
XP_570777.1 (Cryptococcus neoformans var. neoformans JEC21); XP_003194186.1
(Cryptococcus gattii WM276)
8 CNAG_00853 TERYPLTLGR Chr 1: 2257775 – 2257895; Positive - XP_567069.1(Cryptococcus neoformans var. neoformans JEC21), XP_777691.1
(Cryptococcus neoformans var. neoformans B-3501A), XP_003191768.1
(Cryptococcus gattii WM276)
9 CNAG_07863 AELEMLVQR Chr 10: 1004163 – 1004219;
Negative
- XP_567270.1 (Cryptococcus neoformans var. neoformans JEC21), XP_773061.1
(Cryptococcus neoformans var. neoformans B-3501A), XP_003193980.1
(Cryptococcus gattii WM276)
10 CNAG_01261 VTGQSPEDEDWLVGETLDGSHAGGFPK Chr 5: 763635 – 763722; Negative - XP_570166.1 (Cryptococcus neoformans var. neoformans JEC21)
11 CNAG_02407 GGASIFEMVR; GGASIFEmVR Chr 6: 401719 – 401783; Negative - XP_775427.1 (Cryptococcus neoformans var. neoformans B-3501A);
12 CNAG_02292 YDIDLENKR Chr 6: 684574 – 684630; Positive - XP_775540.1 (Cryptococcus neoformans var. neoformans B-3501A);
13 CNAG_02230 FIDPAESGAVIPILHVNGYK Chr 6: 853119 – 853178; Negative - XP_003194389.1 (Cryptococcus gattii WM276); XP_775249.1 (Cryptococcus
neoformans var. neoformans B-3501A); XP_570860.1 (Cryptococcus
neoformans var. neoformans JEC21)
14 CNAG_02147 LLLRPIWKPR Chr 6: 1080395 – 1080490; Positive - XP_775114.1 (Cryptococcus neoformans var. neoformans B-3501A)
15 CNAG_03648 ASSVVTAAYKPLDGEGIFAPAQSTR Chr 2: 436700–436837; Positive - XP_568822.1 (Cryptococcus neoformans var. neoformans JEC21);XP_003192380.1
(Cryptococcus gattii WM276)
16 CNAG_04955 GAVLVNVGR Chr 4: 73400–73459; Negative - XP_568183.1 (Cryptococcus neoformans var. neoformans JEC21); XP_773659.1
(Cryptococcus neoformans var. neoformans B-3501A); XP_003193297.1
(Cryptococcus gattii WM276)
17 CNAG_05059 GLLDKFGEDR Chr 4: 323430–323477; Positive - XP_568096.1 (Cryptococcus neoformans var. neoformans JEC21);
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http://www.clinicalproteomicsjournal.com/content/11/1/5Erroneous annotation of reading frames in hypothetical
proteins is possible as the start codons are only putative
translational initiation sites [31]. Peptide-based evidence
provides unique advantage of confirmation of translational
frame of the annotated gene. MS/MS data search against
six-frame translated genome database identified 10 exonic
peptides in 8 genes, which did not match the annotated
frame of translation of the corresponding gene. These 10
peptides also had orthologous evidence in other serotypes
of Cryptococcus, which indicates that the annotated trans-
lational frame needs to be revised in these exonic regions
of the genes. We were able to determine the correct
reading frame by using peptide evidence. We identi-
fied 3 GSSPs mapping to coding exon 11 and exon
12 of CNAG_05480, the gene coding for hexokinase,
but in a different frame of translation. MS/MS spectra
and details of exonic peptides that altered the translational
frame can be found in Additional file 12: Figure S6 and
Additional file 13: Table S7.
N-terminally acetylated peptide-based confirmation of
translational start sites
Conventionally, protein start sites have been assigned
based on the longest open reading frame and homology-
based comparative genomics [32]. Most eukaryotic pro-
teins are acetylated at their N-termini, usually after the
removal of the initiator methionine. Most often, N-
terminal methionine is cleaved when the second amino
acid residue is any of the following amino acids – Gly,
Ala, Ser, Thr, Cys, Pro or Val. N-terminal Met is generally
retained when the second amino acid is Asp, Glu or Asn
[33]. In some cases, up to 3 amino acid residues can be
removed from the N-terminal end. Identifying N-terminal
acetylated peptides by mass spectrometry is an excellent
method for determining the translational start sites of
proteins [34]. Identification of N-terminally acetylated
peptides and N-terminally semi-tryptic peptides can be
used to determine the translational start sites [24,35]. In
C. neoformans var. grubii, we identified 392 N-terminally
acetylated peptides and 277 peptides with up to 2 amino
acids cleaved from N-terminal end of protein, confirming
the annotated translational start sites of 524 proteins. In
296 proteins, translational start sites were confirmed with
N-terminally acetylated peptides, in 195 proteins, it was
confirmed with identification of non-acetylated N-ter-
minal peptides. In cases of another set of 33 proteins, both
types of peptides were found. Of 392 N-terminally acety-
lated peptides, 104 peptides had modified alanine residue
and 209 peptides had acetylated serine, which is in
agreement with similar findings in most of previous the
investigations on N-terminally acetylated peptides [36]. In
addition, we also identified 2 GSSPs that were acetylated
at the N-termini using our in-house developed cus-
tom N-terminal database to identify novel start sitesof proteins. One of the N-terminally acetylated pep-
tide Ac-SLASCIFCK that mapped upstream to hydrolase
gene (CNAG_03069) extended the protein at its N-
terminus (Figure 5A). This revised and extended protein
sequence is supported by homologous protein in C.
neoformans var. neoformans (XP_569386.1) and C. gattii
(XP_003193163.1). Interestingly, the second N-terminally
acetylated GSSP Ac- AQVVPCLDHPSSYR, besides con-
firming the annotated protein start site of 20 kDa nuclear
cap binding protein, CNAG_05196; also extended the 3′
end of exon 1 into the annotated intron thereby modifying
this gene model (Figure 5B). The modified gene structure
was supported by the presence of similar proteins in C.
neoformans var. neoformans B-3501A (XP_773409.1) and
C. gattii WM276 (XP_003193465.1).
Conclusions
Opportunistic fungal infections are emerging as a serious
threat to human health. Therapeutic interventions to
manage these infections is difficult as many antifungals
have severe side effects [37]. Global molecular profiling of
fungal pathogens will provide a platform for subsequent
comparative genomic and proteomic analyses to identify
molecules that are associated with virulence and patho-
genesis. In this study, we carried out in-depth proteomic
profiling of C. neoformans var. grubii, the most virulent
form among C. neoformans variants. We have provided
protein-coding evidence for 52% of annotated genes from
C. neoformans var. grubii. In addition, we also identified a
large number of novel protein-coding regions, which are
not represented in the current C. neoformans var. grubii
protein database. Genome of Cryptococcus, rich in short
introns, is being explored as a model to understand evolu-
tionarily conserved mechanisms of splicing [38]. In this
study, besides confirming >3,800 annotated splice junc-
tions, proteogenomics helped us identify several novel
splice junctions and revise a number of exon-intron junc-
tions. Similar high-resolution mass spectrometry based
investigation of proteome of the pathogen under different
biological and experimental conditions would provide
differential protein expression data, which will facilitate
our understanding of protein-level changes associated
with pathogenesis.
Methods
Strain and growth conditions
C. neoformans var. grubii culture (MTCC 1353), was ob-
tained from Microbial Type Culture Collection and
Gene Bank resource, Chandigarh in India. The microbe
was cultured in Sabouraud’s Dextrose broth at 37°C until
the cells reached log phase (OD600 = 0.6). Approxima-
tely, 5 × 109 cells were harvested from one litre culture
after centrifugation. The cell pellets were washed ten



















Predicted gene model 
Predicted gene model 
Orthologous evidence in Cryptococcus spp. (Hydrolase - XP_003193163.1) 













Figure 5 Identification of protein start site using N-terminally acetylated peptide. A) N-terminally acetylated peptide Ac-SLAScIFcK identified
upstream to CNAG_03069 corrected the annotated protein start site. B) N-terminally acetylated peptide Ac- AQVVPCLDHPSSYR found overlapping
exon and intron junction confirmed the annotated protein start site and extended the first exon of CNAG_05196.
Nagarajha Selvan et al. Clinical Proteomics 2014, 11:5 Page 11 of 16
http://www.clinicalproteomicsjournal.com/content/11/1/5Protein isolation
The cell pellets were resuspended in 8 M urea and were
then subjected to disruption using glass beads in a cell dis-
ruptor (Disruptor Genei SI-D267, Scientific Industries Inc.
NY) for 30 min at 4°C. Cell lysates were further homoge-
nized by sonication in an ice bath for three 30 sec cycles
with 1 min intervals, using an ultra sonicator (Microson
XL, NY). The samples were then centrifuged at 10,000 × g
for 10 min at 4°C to obtain supernatant. Protein estima-
tion was carried out using Lowry’s assay [39]. Protein
isolated in 8 M urea was used for in solution digestion
followed by peptide fractionation using strong cation
exchange (SCX) chromatography and basic pH reversed-
phase liquid chromatography (bRPLC).
For SDS-PAGE, cell pellets were lyophilized overnight
and then ground in liquid nitrogen using mortar andpestle to obtain a fine powder as described by Crestani
et al. [40]. Samples were then suspended in the buffer
containing 50 mM Tris–HCl, pH 7.5, 1 mM EDTA,
1 mM PMSF. Protein lysates were vortexed for 5 min
and then centrifuged at high speed for 20 min. Super-
natant was collected. Cell debris was resuspended in the
above-mentioned buffer, vortexed for 5 min and sonicated
(three 30 sec cycles with 1 min interval in an icebath).
Supernatant collected after centrifugation was pooled with
the first supernatant. Protein estimation was carried out
using Lowry’s assay.
Trypsin digestion and protein/peptide fractionation
For SDS-PAGE, 250 μg of the protein lysate was resol-
ved using 12% gel and stained with Coomassie blue
stain. The lane was divided into 22 bands and these were
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[41]. The peptides extracted were dried and subjected to
LC-MS/MS analysis. For peptide level fractionation, in so-
lution digestion was carried out as described previously
[41]. Briefly, reduction was carried out by incubating
500 μg of total protein lysate with 5 mM Dithiothreitol
(DTT) at 65°C for 45 min and was then alkylated with
20 mM iodoacetamide at room temperature for 10 min to
irreversibly modify cysteine. The modified protein lysate
was subjected to trypsin digestion at 37°C overnight, with
an enzyme: substrate ratio of 1:20. The digest was then
desalted using Sep-Pak C18 columns (Waters Corporation,
Milford, MA) and lyophilized at −52°C. Subsequently, the
sample was split into two equal halves and fractionated by
SCX [42] and bRPLC [43].
SCX fractionation was carried out on a PolySulfoethyl
A column (PolyLC, Columbia, MD; 200 Å, 5 μm, 200 ×
2.1 mm) using an Agilent 1200 series HPLC system con-
taining a binary pump, autosampler, UV detector and a
fraction collector. Phosphoric acid was added to in-
solution digests to adjust its pH to 2.8 and then diluted to
1 mL using SCX solvent A (10 mM potassium phosphate
buffer in 20% ACN, pH 2.8). Fractionation of peptides
(0.2 mL fractions) was carried out by a linear gradient of
solvent B (10 mM KH2PO4, 350 mM KCl, 20% aceto-
nitrile, pH 2.8) for 70 min. The fractions were completely
dried, reconstituted in 40 μL of 0.1% TFA, desalted using
C18 StageTips and subjected to LC −MS/MS analysis.
bRPLC was performed on XBridge C18, 5 μm 250 ×
4.6 mm analytical column (Waters Corporation, Milford,
MA) with a flow rate of 1 mL/min using an Agilent 1200
series HPLC system. The mobile phase A consisted of
7 mM TEABC in water and B consisted of 7 mM TEABC
in 90% Acetonitrile. Sample separation was accomplished
using the following gradient: 1% B for 0–5 min, 10% B for
5–10 min, 35% B for 10–40 min and 100% B for 40–
45 min. Ninety six fractions were collected in 96 well plate
containing 1% formic acid. The fractions were dried to
half the original volume and were concatenated into 24
fractions by combining 1, 13, 25 and 37; 2, 14, 26 and 38
and so on. These 24 fractions were subjected to LC-MS/
MS analysis.
LC-MS/MS analysis
Nanoflow electrospray ionization tandem mass spectro-
metric analysis of peptide samples was carried out using
LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific,
Bremen, Germany) interfaced with Easy-nLC (Thermo Sci-
entific, Bremen, Germany). The chromatographic capillary
columns used were packed in-house with Magic C18 AQ
(Michrom Bioresources, Inc., Auburn, CA, USA) (5 μm
particle size, pore size 100 Å) reversed phase material in
100% acetonitrile at a pressure of 1000 psi. The peptides
sample from each fraction was enriched on a pre-column(75 μm × 2 cm) at a flow rate of 5 μL/min with solvent A
(0.1% formic acid in water). Peptides were separated on an
analytical column (75 μm × 10 cm) at a flow rate of
350 nL/min using a linear gradient of 7% to 30% solvent B
(0.1% formic acid in 95% acetonitrile) over 60 minutes.
Mass spectrometry analysis was carried out in a data
dependent manner with full scans within 350–1800 m/z
acquired using an Orbitrap mass analyzer at a mass reso-
lution of 60,000 at 400 m/z. For each duty cycle, twenty
most intense precursor ions from a survey scan were
selected for MS/MS and detected at a mass resolution of
15,000 at m/z of 400, also in an Orbitrap analyzer. The
fragmentation was carried out using higher-energy colli-
sion dissociation (HCD) with 39% normalized collision
energy. Dynamic exclusion was set for 30 seconds with a
10 ppm mass window. The automatic gain control for full
FT MS was set to 0.5 million ions and for FT MS/MS was
set to 0.1 million ions with a maximum ion injection times
of 100 ms and 200 ms, respectively. Internal calibration was
done using lock-mass from ambient air (m/z 445.1200025)
as described previously [44]. Other parameters include
spray voltage of 2.0 kV, capillary voltage of 250. The
raw data obtained was submitted to ProteomeCommons
(https://www.proteomecommons.org/).
Database searches for peptide identification
Proteome Discoverer version 1.3 (Thermo Scientific) plat-
form integrated with Sequest and Mascot search engines
was used to search the mass spectrometry data against
protein and other customized databases. The protein
database consisted of 6,980 protein sequences, which
included protein sequences encoded by genome (6,967)
and mitochondrial genome (13) of C. neoformans var.
grubii downloaded from the genome database at Broad
Institute (gene set version 4.0) (http://www.broadinstitute.
org/annotation/genome/cryptococcus_neoformans/Multi
Home.html) [6] and common contaminants. Carbamido-
methylation of cysteine was used as fixed modification
whereas oxidation of methionine and protein N-terminal
acetylation were used as variable modifications. A maxi-
mum of one missed cleavage, mass deviation of 20 ppm
and 0.1 Da were allowed for MS and MS/MS, respectively.
False discovery rate of 1%, as calculated by enabling the
peptide sequence analysis using decoy database, was used
as a cut-off value for reporting identified peptides. The
peptide and protein data were extracted using high pep-
tide confidence and top one peptide rank filters. Relative
abundance of proteins in C. neoformans var. grubii was
determined by calculating normalized spectral abundance
factors (NSAF) for each protein identified in the study as
previously described [45]. NSAF for a protein k was calcu-
lated as dividing the total number of peptide spectral
matches (S) identified for protein k by protein length (L)
and then divided by the sum of S/L ratio for all proteins.
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The whole genome sequence of Cryptococcus neofor-
mans var. grubii was downloaded from Broad Institute’s
website and translated into six reading frames. These
translated sequences were fetched as amino acid sequen-
ces from stop codon to the next stop codon, stored in a
database as a six-frame translated genome database.
The peptide data obtained from MS/MS data searches
against six-frame translated genome database were
compared with protein database to find unique peptides,
which are not represented in proteins database. These
peptides were referred to as “genome search specific pep-
tides (GSSPs).” GSSPs were mapped on to the genome by
tblastn and the genomic co-ordinates of these peptides
were fetched. Only those GSSPs which mapped to single
locus in the genome were considered for further analysis.
Based on the genomic regions they mapped to, these
GSSPs were classified as follows: (i) peptides mapping to
intergenic regions; (ii) peptides mapping to UTRs; (iii)
peptides mapping to introns; (iv) peptides mapping to
junctions of exon–intron; (v) peptides mapping to coding
exons but translated in a different frame; and (vi) peptides
mapping onto gene boundaries. Peptides that overlapped
with annotated gene models were used to correct the
existing gene annotation. The intergenic peptides were
analyzed to identify novel protein-coding regions. Com-
parative genome analysis of the genomic region flanking
GSSPs and/or alternative gene models by various predic-
tion programs – Augustus [46], Geneid [47], GLEAN [48],
GeneMark [49] and Twinscan [50], which were incorpo-
rated in the Broad Institute’s genome browser were used
to determine the novel gene models.
Most eukaryotic proteins are known to be N-termin-
ally modified. Translational start sites can be determined
by identifying N-terminally acetylated peptides [35,51].
Since we allowed identification of only tryptic peptides
from genome database, novel protein N-terminal pepti-
des could not be identified as they appear as semitryptic
peptides in the six frame translated genome sequences.
Hence, from the six-frame translated genome database,
we created a separate database of potential N-terminal
peptides starting with methionine and ending with either
lysine or arginine with sequence length from 7 amino
acids to 15 amino acids. MS/MS data was searched against
this database using Mascot search engine, while defining
variable modification of protein N-terminal acetylation.
As with Mascot search engine it is possible to identify pro-
tein N-terminal peptides with or without cleaved initiator
methionine, we could identify peptides with N-terminal
acetylation at second amino acid or initiator methionine.
Validation of gene models by RT-PCR
A subset of novel or revised gene models was validated
using RT-PCR followed by cDNA sequencing. Genemodel specific primers were designed using Primer3 soft-
ware [52]. The primers were designed to span the revised
regions and designed across exons. Total RNA was
isolated from mid log phase culture of C. neoformans var.
grubii as described by Yang et al. [53]. Briefly, cell pellet
obtained from 50 mL culture was washed 10 times with
ice cold PBS and lyophilized overnight. The pellets were
ground using liquid nitrogen and suspended in 1 mL
Qiazol (Catalog No. 79306, Qiagen, Valencia, CA). The
suspension was brought to room temperature. To the sus-
pension, 200 μL of chloroform was added and mixed well.
The tubes were then incubated at room temperature for
10 min and later centrifuged at high speed for 15 min at
4°C. The upper aqueous phase was separated and collected
in a fresh tube. RNA was precipitated with 500 μL of iso-
propanol by incubating at room temperature for 15 min
followed by centrifugation at high speed for 15 min at 4°C.
The pellet was washed with 70% ethanol and dried. The
pellet was suspended in 50 μL of RNase free water. RNA
was then subjected to DNase treatment to remove any
genomic DNA using RNeasy mini kit (Catalog No. 74104,
Qiagen, Valencia, CA) following manufacturer’s instruc-
tions. cDNA synthesis was carried out with about 1 μg of
total RNA using QuantiTect Reverse Transcription kit
(Catalog No. 205311, Qiagen, Valencia, CA). PCR was car-
ried out using 1 μL of cDNA, 0.1 μM of each forward and
reverse primers, 1.5 mM MgCl2 0.2 mM dNTP mix, 1.5U
of Taq polymerase and PCR buffer in 50 μl reaction vol-
ume. Thermal cycling conditions performed to amplify
the target sequence comprised initial denaturation cycle
of 95°C for 3 min, 40 cycles of amplification with 95°C for
15 sec, 55°C for 60 sec and 72°C for 30 sec. The list of for-
ward and reverse primers used for validation is provided
in Additional file 14: Table S8. PCR carried out with RNA
served as negative control. Amplicon sizes were deter-
mined by running 5 μL of reaction on 1.5% agarose gel
along with 100 bp DNA ladder. PCR products were
subjected to PCR clean up using Qiaquick PCR purifi-
cation kit (Catalog No. 28104, Qiagen, Valencia, CA). The
purified products were sequenced using Applied Bio-
systems 3730xl DNA analyzer Big Dye Terminator.
cDNA sequences thus obtained were submitted to
GenBank.
Data availability
The data associated with this manuscript can be down-
loaded from the ProteomeCommons.org Tranche network
using the following hash:
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(FGLNTPGAR) of CNAG_02460. Based on comparative genomics and
predicted models, annotated exon boundaries of CNAG_02460 were
revised. B) Representative MS/MS spectrum of intronic peptide is
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peptide evidence.
Additional file 9: Figure S4. Extension of gene model using intergenic
peptide A) Peptide mapped to upstream of gene CNAG_05600.
Extension of protein comprising this peptide is supported by predicted
models and homologous proteins in C. neoformans var. neoformans. B)
Representative MS/MS spectrum of the intergenic peptide is illustrated.
Additional file 10: Table S6. List of peptides providing protein-coding
evidence of UTRs of genes.
Additional file 11: Figure S5. Protein-coding evidence for regions
annotated as UTR A) Three peptides mapped to 3′ UTR of CNAG_00768.
Orthologous proteins from Cryptococcus spp. and prediction models
support the extension of protein at C – terminus. B) Representative
MS/MS spectrum of EGYYELCIK peptide is provided.
Additional file 12: Figure S6. MS/MS spectra of 4 GSSPs mapping to
exonic regions of annotated gene that were used to correct the
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